Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.
Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.
复制标题
DOI：
10.1111/jcmm.16198
复制
发表时间：
2021-01
影响因子：
5.3
通讯作者：
Wang DW
中科院分区：
文献类型：
--
作者：
Yuan S;Chen P;Li H;Chen C;Wang F;Wang DW
确定住院前使用阿司匹林是否与2019冠状病毒病（COVID-19）冠状动脉疾病（CAD）患者的全因死亡率相关。我们招募了183名确诊为COVID-19的成人CAD患者，其中52名服用低剂量阿司匹林（平均[SD]年龄，69.7 [1.1]岁; 59.6%男性）和131例未使用阿司匹林（平均[SD]年龄，71.8 [0.9]岁; 51.9%为男性），于2020年1月10日至2020年3月30日在中国武汉同济医院住院。阿司匹林组和非阿司匹林组的住院死亡率无差异（21.2% vs. 22.1%，P = 0.885）。同样，对于重症COVID-19患者，阿司匹林组的死亡率接近非阿司匹林组（44% vs. 45.9%，P = 0.872）。此外，存活者和非存活者之间服用低剂量阿司匹林的CAD患者百分比没有差异（28.7% vs. 27.5%，P = .885）。同时，在多变量分析中，阿司匹林的使用与全因死亡率无关（OR = 0.944，95% CI：0.411 - 2.172，P = 0.893）。总的来说，我们的研究表明，住院前使用低剂量阿司匹林与因COVID-19感染住院的CAD患者的临床结局无关。
To determine whether pre‐hospitalization use of aspirin is associated with all‐cause mortality in coronavirus disease 2019 (COVID‐19) patients with coronary artery disease (CAD). We recruited 183 adult patients with CAD diagnosed with COVID‐19, including 52 taking low‐dose aspirin (mean [SD] age, 69.7 [1.1] years; 59.6% men) and 131 without using aspirin (mean [SD] age, 71.8 [0.9] years; 51.9% men), who were admitted in the Tongji hospital in Wuhan, China from January 10, 2020 to March 30, 2020. There was no difference on in‐hospital mortality between aspirin group and non‐aspirin group (21.2% vs. 22.1%, P = .885). Similarly, for critically severe COVID‐19 patients, the mortality in aspirin group was close to that in non‐aspirin group (44% vs. 45.9%, P = .872). Moreover, the percentage of patients with CAD taking low‐dose aspirin did not differ between those survivors and non‐survivors (28.7% vs. 27.5%, P = .885). Meanwhile, the usage of aspirin was not correlated with all‐cause mortality in multivariate analysis (OR = 0.944, 95% CI: 0.411‐2.172, P = .893). Collectively, our study suggested that the pre‐hospitalization use of low‐dose aspirin was not associated with the clinical outcome of patients with CAD hospitalized with COVID‐19 infections.
登录
查看更多内容
影响因子：
5.8
作者：
Asghar, Waheed;Aghazadeh-Habashi, Ali;Jamali, Fakhreddin
通讯作者：
Jamali, Fakhreddin
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John
影响因子：
5
作者：
Lippi, Giuseppe;Plebani, Mario;Henry, Brandon Michael
通讯作者：
Henry, Brandon Michael
中国武汉市 138 例 2019 新型冠状病毒感染肺炎住院患者的临床特征。
影响因子：
120.7
作者：
Wang, Dawei;Hu, Bo;Peng, Zhiyong
通讯作者：
Peng, Zhiyong
影响因子：
1.8
作者：
Russell, Beth;Moss, Charlotte;Van Hemelrijck, Mieke
通讯作者：
Van Hemelrijck, Mieke